Latest news with #Intas
Korea Herald
18 hours ago
- Business
- Korea Herald
Intas & Accord signs Agreement to acquire Prothya Biosolutions
AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly. This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global presence in the PDMP market, expanding Intas's established leadership in India into a truly international footprint. Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary, employs approximately 1,200 people. The company is one of Europe's largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs. Binish Chudgar, Chairman of Intas & Accord, stated: "We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies." Intas's plasma division in India has been supplying hospitals with PDMPs since 2015, supported by an annual fractionation capacity of over 1 million litres and exports to multiple international markets. Additional capacity is due to come online with the expansion of Intas's Gujarat-based facility. Nir Epstein, CEO of Prothya, commented: "Over the past four years, we've expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary, and supplied plasma derivatives to some of the world's leading PDMP companies—all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion." The global market for PDMPs—particularly IVIG (intravenous immunoglobulin)—is currently valued at $30 billion and is expected to reach $50 billion by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord's commercial footprint spanning 85 countries. BofA Securities is acting as the exclusive financial advisor to Accord in this transaction. Evercore is acting as the exclusive financial advisor to Prothya in this transaction. About Intas: Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs. Intas also has strong in-house biosimilar development and marketing capabilities, with more than 15 products being marketed. Intas is committed to expanding global healthcare access by providing affordable, high-quality medications through strategic partnerships and extensive R&D investment to meet the diverse needs of healthcare systems around the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare, to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas's remarkable success in North America and European operations has helped us emerge as a global brand in the world's largest pharmaceutical markets.
Cision Canada
2 days ago
- Business
- Cision Canada
Intas & Accord signs Agreement to acquire Prothya Biosolutions
AHMEDABAD, India, Aug. 11, 2025 /CNW/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly. This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global presence in the PDMP market, expanding Intas's established leadership in India into a truly international footprint. Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary, employs approximately 1,200 people. The company is one of Europe's largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs. Binish Chudgar, Chairman of Intas & Accord, stated: "We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies." Intas's plasma division in India has been supplying hospitals with PDMPs since 2015, supported by an annual fractionation capacity of over 1 million litres and exports to multiple international markets. Additional capacity is due to come online with the expansion of Intas's Gujarat-based facility. Nir Epstein, CEO of Prothya, commented: "Over the past four years, we've expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary, and supplied plasma derivatives to some of the world's leading PDMP companies—all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion." The global market for PDMPs—particularly IVIG (intravenous immunoglobulin)—is currently valued at $30 billion and is expected to reach $50 billion by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord's commercial footprint spanning 85 countries. BofA Securities is acting as the exclusive financial advisor to Accord in this transaction. Evercore is acting as the exclusive financial advisor to Prothya in this transaction. About Intas: Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs. Intas also has strong in-house biosimilar development and marketing capabilities, with more than 15 products being marketed. Intas is committed to expanding global healthcare access by providing affordable, high-quality medications through strategic partnerships and extensive R&D investment to meet the diverse needs of healthcare systems around the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare, to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas's remarkable success in North America and European operations has helped us emerge as a global brand in the world's largest pharmaceutical markets.
Business Standard
6 days ago
- Business
- Business Standard
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
PRNewswire Ahmedabad (Gujarat) [India], August 7: Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc. UDENYCA®, a biosimilar to Neulasta® (pegfilgrastim), significantly expands Intas and Accord's FDA-approved biosimilar portfolio and accelerates their strategic growth in the global biosimilar market. Accord is already a pegfilgrastim market leader in Europe--having been the first to commercialize a biosimilar pegfilgrastim and the only company to launch an autoinjector-- has maintained its leadership despite intense competition. This acquisition further strengthens the company's presence and impact in both the U.S. and international biosimilar landscapes. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA® to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA® offers three patient-friendly administration options--autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)--providing flexibility for treatment at home, on-the-go, or in clinical settings. Since its commercial launch, over 300,000 patients have been treated with UDENYCA® and more than 1.4 million units have been distributed. The acquisition not only expands Accord BioPharma's product offerings but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, who have joined Accord BioPharma, will play a crucial role in supply and services continuity/transition and expanding the company's work around UDENYCA®. Paul Tredwell, EMENA Executive Vice-President of Accord, added: "With the Accord Biopharma team now fully commercializing UDENYCA® in three different formulations, this development strengthens Accord's offering and advances our goal of becoming the world's leading supplier of pegfilgrastim." UDENYCA® (pegfilgrastim-cbqv) INDICATION UDENYCA® is a leukocyte growth factor indicated to: * Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. * Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). Limitations of Use UDENYCA® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. IMPORTANT SAFETY INFORMATION CONTRAINDICATION: Patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis. WARNINGS AND PRECAUTIONS: - Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. - Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA® in patients with ARDS. - Serious allergic reactions, including anaphylaxis: The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue UDENYCA® in patients with serious allergic reactions. - Allergies to Acrylics (UDENYCA ONBODY® only): The on-body injector (OBI) for UDENYCA® uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in a significant reaction. - Sickle cell crises: Severe and sometimes fatal crises have occurred. Discontinue UDENYCA® if sickle cell crisis occurs. - Glomerulonephritis: The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events resolved after dose reduction or discontinuation. Evaluate and consider dose-reduction or interruption of UDENYCA® if causality is likely. - Leukocytosis: White blood cell (WBC) counts of 100 x 109/L or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count (CBC) during UDENYCA® therapy is recommended. - Thrombocytopenia: Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor platelet counts. - Capillary Leak Syndrome: Has been reported after G-CSF administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. If symptoms develop, closely monitor and give standard symptomatic treatment, which may include a need for intensive care. - Potential for Tumor Growth Stimulatory Effects on Malignant Cells: The granulocyte colony stimulating factor (G-CSF) receptor through which pegfilgrastim products and filgrastim products act has been found on tumor cell lines. The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded. - Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer: MDS and AML have been associated with the use of pegfilgrastim in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings. - Potential Device failures ( UDENYCA ONBODY® only): Missed or partial doses have been reported for products administered via on-body injectors due to the device not performing as intended. In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered. Instruct patients using the OBI to notify their healthcare professional immediately to determine the need for a replacement dose of UDENYCA® if they suspect that the device may not have performed as intended. - Aortitis: Has been reported in patients receiving pegfilgrastim products, occurring as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis when signs and symptoms develop without known etiology. Discontinue UDENYCA® if aortitis is suspected. - Nuclear Imaging: Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. Consider when interpreting bone imaging results. ADVERSE REACTIONS: Most common adverse reactions (>= 5% difference in incidence compared to placebo) are bone pain and pain in extremity. To report SUSPECTED ADVERSE REACTIONS, contact 1-800-4-UDENYCA (1-800-483-3692) or notify the FDA at 1-800-FDA-1088 or UDENYCA® Prefilled Syringe: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only. UDENYCA® Autoinjector: 6 mg/0.6 mL in a single-dose prefilled autoinjector. UDENYCA ONBODY®: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector for UDENYCA®. Advisors Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. acted as legal counsel to Accord and Intas with respect to the Transaction. About Intas Pharmaceuticals Intas Pharmaceuticals is a pioneer in biosimilars, having developed and launched one of the highest numbers of indigenous biosimilars in India. Intas Pharmaceuticals has a rich history of making quality biosimilars accessible to the masses in India. Intas' products like Neukine (filgrastim), Pegasta (Pegfilgrastim), Mabtas (rituximab), Razumab (ranibizumab) and Bevatas (bevacizumab) have transformed the management of their respective therapies in India. Eleftha is the latest testament to Intas' Biosimilar for Billions philosophy, fulfilling its commitment to provide quality care to the masses in India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit About Accord BioPharma Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients' perspective and develop high-quality therapies that impact patients' lives. Accord BioPharma believes in the ability of biosimilars to increase access to a number of biologic medicines, that in the past may not have been considered for patients due to their high costs. Accord BioPharma looks forward to providing one of the deepest biosimilar portfolios in the industry. For more information, visit About Coherus BioSciences Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology. References: 1. UDENYCA® Prescribing Information. Coherus BioSciences; December 2023. All trademarks, logos and brand names are the property of their respective owners. Logo:
Yahoo
15-04-2025
- Business
- Yahoo
Coherus divests Udenyca franchise to Intas for up to $558.4m
Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up to $558.4m. Coherus obtained $483.4m in cash upfront on its completion, and $118.4m for the therapy's inventory. The amount is subject to post-closing adjustments. Coherus now stands to gain a further $75m in two separate milestone payments, contingent upon Intas achieving net sales targets for the therapy. Intas obtained identified assets associated with the therapy franchise, which include the pre-filled syringe, the autoinjector and the Udenyca Onbody, while also taking on certain specified liabilities. Coherus was advised by JP Morgan Securities for the financial aspects of the transaction, while Latham & Watkins provided legal advisory services to the company. Coherus BioSciences CEO and chairman Denny Lanfear stated: 'With strong strategic execution, we have transformed the company while dramatically reducing our debt and leaving $250m on the post-close balance sheet. 'This provides ample runway to achieve our mid-term corporate objectives, including maximising Loqtorzi revenues, advancing our novel immuno-oncology candidates in combination with Loqtorzi to key data milestones in 2026, and progressing label-expanding indications for Loqtorzi in novel combinations.' During the transaction's closure, Intas' US speciality division Accord BioPharma took over complete responsibility for the therapy's franchise in the country. Accord is now set to make the therapy available for reducing infection incidence in individuals with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. The acquisition not only broadens Accord's product portfolio but also incorporates key employees of Coherus into its team. These employees will contribute to the ongoing development and expansion of the therapy across marketing, sales, supply chain, finance and quality, and manufacturing. "Coherus divests Udenyca franchise to Intas for up to $558.4m" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
